Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 17 entries
Sorted by: Best Match Show Resources per page
Clinical validation of genetic variants associated with .

Oncotarget

Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L.
PMID: 29100455
Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29.

Hematotoxicity is one of the major side effects of chemotherapy. The aim of this study was to examine the association between single nucleotide polymorphisms (SNPs) and hematotoxicity in breast cancer patients in a subset of patients of the SUCCESS...

Cite
Fasching PA, Häberle L, Rack B, et al. Clinical validation of genetic variants associated with . Oncotarget. 2017;8(44):78133-78143doi: 10.18632/oncotarget.17726.
Fasching, P. A., Häberle, L., Rack, B., Li, L., Hein, A., Ekici, A. B., Reis, A., Lux, M. P., Cunningham, J. M., Ruebner, M., Jenkins, G., Fridley, B., Schneeweiss, A., Tesch, H., Lichtenegger, W., Fehm, T., Heinrich, G., Rezai, M., Beckmann, M. W., Janni, W., Weinshilboum, R. M., & Wang, L. (2017). Clinical validation of genetic variants associated with . Oncotarget, 8(44), 78133-78143. https://doi.org/10.18632/oncotarget.17726
Fasching, Peter A, et al. "Clinical validation of genetic variants associated with ." Oncotarget vol. 8,44 (2017): 78133-78143. doi: https://doi.org/10.18632/oncotarget.17726
Fasching PA, Häberle L, Rack B, Li L, Hein A, Ekici AB, Reis A, Lux MP, Cunningham JM, Ruebner M, Jenkins G, Fridley B, Schneeweiss A, Tesch H, Lichtenegger W, Fehm T, Heinrich G, Rezai M, Beckmann MW, Janni W, Weinshilboum RM, Wang L. Clinical validation of genetic variants associated with . Oncotarget. 2017 May 09;8(44):78133-78143. doi: 10.18632/oncotarget.17726. eCollection 2017 Sep 29. PMID: 29100455; PMCID: PMC5652844.
Copy Download .nbib Format: NLM
Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma.

Journal of translational medicine

Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ, Bulur PA, Allred JB, Creagan ET, Ingle JN, Gastineau DA, Vuk-Pavlovic S.
PMID: 16911798
J Transl Med. 2006 Aug 15;4:35. doi: 10.1186/1479-5876-4-35.

BACKGROUND: Dendritic cells (DCs) have been used as vaccines in clinical trials of immunotherapy of cancer and other diseases. Nonetheless, progress towards the use of DCs in the clinic has been slow due in part to the absence of...

Cite
Markovic SN, Dietz AB, Greiner CW, et al. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med. 2006;4:35doi: 10.1186/1479-5876-4-35.
Markovic, S. N., Dietz, A. B., Greiner, C. W., Maas, M. L., Butler, G. W., Padley, D. J., Bulur, P. A., Allred, J. B., Creagan, E. T., Ingle, J. N., Gastineau, D. A., & Vuk-Pavlovic, S. (2006). Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. Journal of translational medicine, 435. https://doi.org/10.1186/1479-5876-4-35
Markovic, Svetomir N, et al. "Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma." Journal of translational medicine vol. 4 (2006): 35. doi: https://doi.org/10.1186/1479-5876-4-35
Markovic SN, Dietz AB, Greiner CW, Maas ML, Butler GW, Padley DJ, Bulur PA, Allred JB, Creagan ET, Ingle JN, Gastineau DA, Vuk-Pavlovic S. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med. 2006 Aug 15;4:35. doi: 10.1186/1479-5876-4-35. PMID: 16911798; PMCID: PMC1570143.
Copy Download .nbib Format: NLM
Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer.

American journal of cancer research

Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV.
PMID: 22206049
Am J Cancer Res. 2012;2(1):104-15. Epub 2011 Nov 21.

PURPOSE: To determine the prognostic value of FOXO1, GATA3 and Annexin-1 expression in breast cancer.METHODS: Tissue microarray and individual paraffin tissue slides from 131 patients were used for the study. The association of FOXO1, GATA3 and Annexin-1 expression with...

Cite
Wu Y, Elshimali Y, Sarkissyan M, et al. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2011;2(1):104-15
Wu, Y., Elshimali, Y., Sarkissyan, M., Mohamed, H., Clayton, S., & Vadgama, J. V. (2012). Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. American journal of cancer research, 2(1), 104-15.
Wu, Yanyuan, et al. "Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer." American journal of cancer research vol. 2,1 (2012): 104-15.
Wu Y, Elshimali Y, Sarkissyan M, Mohamed H, Clayton S, Vadgama JV. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am J Cancer Res. 2012;2(1):104-15. Epub 2011 Nov 21. PMID: 22206049; PMCID: PMC3236574.
Copy Download .nbib Format: NLM
Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in .

Drug metabolism and disposition: the biological fate of chemicals

Devarajan S, Moon I, Ho MF, Larson NB, Neavin DR, Moyer AM, Black JL, Bielinski SJ, Scherer SE, Wang L, Weinshilboum RM, Reid JM.
PMID: 30745309
Drug Metab Dispos. 2019 Apr;47(4):425-435. doi: 10.1124/dmd.118.084269. Epub 2019 Feb 11.

No abstract available.

Cite
Devarajan S, Moon I, Ho MF, et al. Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in . Drug Metab Dispos. 2019;47(4):425-435doi: 10.1124/dmd.118.084269.
Devarajan, S., Moon, I., Ho, M. F., Larson, N. B., Neavin, D. R., Moyer, A. M., Black, J. L., Bielinski, S. J., Scherer, S. E., Wang, L., Weinshilboum, R. M., & Reid, J. M. (2019). Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in . Drug metabolism and disposition: the biological fate of chemicals, 47(4), 425-435. https://doi.org/10.1124/dmd.118.084269
Devarajan, Sandhya, et al. "Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in ." Drug metabolism and disposition: the biological fate of chemicals vol. 47,4 (2019): 425-435. doi: https://doi.org/10.1124/dmd.118.084269
Devarajan S, Moon I, Ho MF, Larson NB, Neavin DR, Moyer AM, Black JL, Bielinski SJ, Scherer SE, Wang L, Weinshilboum RM, Reid JM. Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in . Drug Metab Dispos. 2019 Apr;47(4):425-435. doi: 10.1124/dmd.118.084269. Epub 2019 Feb 11. PMID: 30745309; PMCID: PMC6423619.
Copy Download .nbib Format: NLM
Dose modification for safe treatment of a compound complex heterozygous .

JCO precision oncology

Shrestha S, Tapper EE, Trogstad-Isaacson CS, Hobday TJ, Offer SM, Diasio RB.
PMID: 32039342
JCO Precis Oncol. 2018;2. doi: 10.1200/po.18.00179. Epub 2018 Oct 03.

No abstract available.

Cite
Shrestha S, Tapper EE, Trogstad-Isaacson CS, et al. Dose modification for safe treatment of a compound complex heterozygous . JCO Precis Oncol. 2018;2doi: 10.1200/po.18.00179.
Shrestha, S., Tapper, E. E., Trogstad-Isaacson, C. S., Hobday, T. J., Offer, S. M., & Diasio, R. B. (2018). Dose modification for safe treatment of a compound complex heterozygous . JCO precision oncology, 2. https://doi.org/10.1200/po.18.00179
Shrestha, Shikshya, et al. "Dose modification for safe treatment of a compound complex heterozygous ." JCO precision oncology vol. 2 (2018). doi: https://doi.org/10.1200/po.18.00179
Shrestha S, Tapper EE, Trogstad-Isaacson CS, Hobday TJ, Offer SM, Diasio RB. Dose modification for safe treatment of a compound complex heterozygous . JCO Precis Oncol. 2018;2. doi: 10.1200/po.18.00179. Epub 2018 Oct 03. PMID: 32039342; PMCID: PMC7006951.
Copy Download .nbib Format: NLM
Decreased Expression of Sulfatase 2 in the Brains of Alzheimer's Disease Patients: Implications for Regulation of Neuronal Cell Signaling.

Journal of Alzheimer's disease reports

Roberts RO, Kang YN, Hu C, Moser CD, Wang S, Moore MJ, Graham RP, Lai JP, Petersen RC, Roberts LR.
PMID: 30035253
J Alzheimers Dis Rep. 2017;1(1):115-124. doi: 10.3233/ADR-170028. Epub 2017 Sep 28.

BACKGROUND: The human sulfatase 1 (SULF1) and sulfatase 2 (SULF2) genes modulate cell signaling and homeostasis in many tissues. Gene expression analyses have implicated SULF2 in disease pathogenesis, including Alzheimer's disease (AD), but changes in brain SULF2 expression have...

Cite
Roberts RO, Kang YN, Hu C, et al. Decreased Expression of Sulfatase 2 in the Brains of Alzheimer's Disease Patients: Implications for Regulation of Neuronal Cell Signaling. J Alzheimers Dis Rep. 2017;1(1):115-124doi: 10.3233/ADR-170028.
Roberts, R. O., Kang, Y. N., Hu, C., Moser, C. D., Wang, S., Moore, M. J., Graham, R. P., Lai, J. P., Petersen, R. C., & Roberts, L. R. (2017). Decreased Expression of Sulfatase 2 in the Brains of Alzheimer's Disease Patients: Implications for Regulation of Neuronal Cell Signaling. Journal of Alzheimer's disease reports, 1(1), 115-124. https://doi.org/10.3233/ADR-170028
Roberts, Rosebud O, et al. "Decreased Expression of Sulfatase 2 in the Brains of Alzheimer's Disease Patients: Implications for Regulation of Neuronal Cell Signaling." Journal of Alzheimer's disease reports vol. 1,1 (2017): 115-124. doi: https://doi.org/10.3233/ADR-170028
Roberts RO, Kang YN, Hu C, Moser CD, Wang S, Moore MJ, Graham RP, Lai JP, Petersen RC, Roberts LR. Decreased Expression of Sulfatase 2 in the Brains of Alzheimer's Disease Patients: Implications for Regulation of Neuronal Cell Signaling. J Alzheimers Dis Rep. 2017;1(1):115-124. doi: 10.3233/ADR-170028. Epub 2017 Sep 28. PMID: 30035253; PMCID: PMC6052874.
Copy Download .nbib Format: NLM
Evaluation of a new high-dimensional miRNA profiling platform.

BMC medical genomics

Cunningham JM, Oberg AL, Borralho PM, Kren BT, French AJ, Wang L, Bot BM, Morlan BW, Silverstein KA, Staggs R, Zeng Y, Lamblin AF, Hilker CA, Fan JB, Steer CJ, Thibodeau SN.
PMID: 19712457
BMC Med Genomics. 2009 Aug 27;2:57. doi: 10.1186/1755-8794-2-57.

BACKGROUND: MicroRNAs (miRNAs) are a class of approximately 22 nucleotide long, widely expressed RNA molecules that play important regulatory roles in eukaryotes. To investigate miRNA function, it is essential that methods to quantify their expression levels be available.METHODS: We...

Cite
Cunningham JM, Oberg AL, Borralho PM, et al. Evaluation of a new high-dimensional miRNA profiling platform. BMC Med Genomics. 2009;2:57doi: 10.1186/1755-8794-2-57.
Cunningham, J. M., Oberg, A. L., Borralho, P. M., Kren, B. T., French, A. J., Wang, L., Bot, B. M., Morlan, B. W., Silverstein, K. A., Staggs, R., Zeng, Y., Lamblin, A. F., Hilker, C. A., Fan, J. B., Steer, C. J., & Thibodeau, S. N. (2009). Evaluation of a new high-dimensional miRNA profiling platform. BMC medical genomics, 257. https://doi.org/10.1186/1755-8794-2-57
Cunningham, Julie M, et al. "Evaluation of a new high-dimensional miRNA profiling platform." BMC medical genomics vol. 2 (2009): 57. doi: https://doi.org/10.1186/1755-8794-2-57
Cunningham JM, Oberg AL, Borralho PM, Kren BT, French AJ, Wang L, Bot BM, Morlan BW, Silverstein KA, Staggs R, Zeng Y, Lamblin AF, Hilker CA, Fan JB, Steer CJ, Thibodeau SN. Evaluation of a new high-dimensional miRNA profiling platform. BMC Med Genomics. 2009 Aug 27;2:57. doi: 10.1186/1755-8794-2-57. PMID: 19712457; PMCID: PMC2744682.
Copy Download .nbib Format: NLM
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine.

Chinese clinical oncology

Mandrekar SJ, Sargent DJ.
PMID: 25414851
Chin Clin Oncol. 2014 Jun 01;3(2):14. doi: 10.3978/j.issn.2304-3865.2014.05.03.

In the current era of stratified medicine and biomarker-driven therapies, the focus has shifted from predictions based on the traditional anatomic staging systems to guide the choice of treatment for an individual patient to an integrated approach using the...

Cite
Mandrekar SJ, Sargent DJ. Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. Chin Clin Oncol. 2014;3(2):14doi: 10.3978/j.issn.2304-3865.2014.05.03.
Mandrekar, S. J., & Sargent, D. J. (2014). Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. Chinese clinical oncology, 3(2), 14. https://doi.org/10.3978/j.issn.2304-3865.2014.05.03
Mandrekar, Sumithra J, and Sargent, Daniel J. "Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine." Chinese clinical oncology vol. 3,2 (2014): 14. doi: https://doi.org/10.3978/j.issn.2304-3865.2014.05.03
Mandrekar SJ, Sargent DJ. Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. Chin Clin Oncol. 2014 Jun 01;3(2):14. doi: 10.3978/j.issn.2304-3865.2014.05.03. PMID: 25414851; PMCID: PMC4236025.
Copy Download .nbib Format: NLM
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation.

Chinese clinical oncology

Renfro LA, Coughlin CM, Grothey AM, Sargent DJ.
PMID: 25485277
Chin Clin Oncol. 2014 Mar 01;3(1). doi: 10.3978/j.issn.2304-3865.2013.12.04.

BACKGROUND: Frequently a biomarker capable of defining a patient population with enhanced response to an experimental agent is not fully validated with a known threshold at the start of a phase II trial. When such candidate predictive markers are...

Cite
Renfro LA, Coughlin CM, Grothey AM, et al. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chin Clin Oncol. 2014;3(1)doi: 10.3978/j.issn.2304-3865.2013.12.04.
Renfro, L. A., Coughlin, C. M., Grothey, A. M., & Sargent, D. J. (2014). Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chinese clinical oncology, 3(1), . https://doi.org/10.3978/j.issn.2304-3865.2013.12.04
Renfro, Lindsay A, et al. "Adaptive randomized phase II design for biomarker threshold selection and independent evaluation." Chinese clinical oncology vol. 3,1 (2014). doi: https://doi.org/10.3978/j.issn.2304-3865.2013.12.04
Renfro LA, Coughlin CM, Grothey AM, Sargent DJ. Adaptive randomized phase II design for biomarker threshold selection and independent evaluation. Chin Clin Oncol. 2014 Mar 01;3(1). doi: 10.3978/j.issn.2304-3865.2013.12.04. PMID: 25485277; PMCID: PMC4255950.
Copy Download .nbib Format: NLM
Epithelial-Mesenchymal Transition and Breast Cancer.

Journal of clinical medicine

Wu Y, Sarkissyan M, Vadgama JV.
PMID: 26821054
J Clin Med. 2016 Jan 26;5(2). doi: 10.3390/jcm5020013.

Breast cancer is the most common cancer in women and distant site metastasis is the main cause of death in breast cancer patients. There is increasing evidence supporting the role of epithelial-mesenchymal transition (EMT) in tumor cell progression, invasion,...

Cite
Wu Y, Sarkissyan M, Vadgama JV. Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med. 2016;5(2)doi: 10.3390/jcm5020013.
Wu, Y., Sarkissyan, M., & Vadgama, J. V. (2016). Epithelial-Mesenchymal Transition and Breast Cancer. Journal of clinical medicine, 5(2), . https://doi.org/10.3390/jcm5020013
Wu, Yanyuan, et al. "Epithelial-Mesenchymal Transition and Breast Cancer." Journal of clinical medicine vol. 5,2 (2016). doi: https://doi.org/10.3390/jcm5020013
Wu Y, Sarkissyan M, Vadgama JV. Epithelial-Mesenchymal Transition and Breast Cancer. J Clin Med. 2016 Jan 26;5(2). doi: 10.3390/jcm5020013. PMID: 26821054; PMCID: PMC4773769.
Copy Download .nbib Format: NLM
Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall.

Oncotarget

Moyer AM, Yu J, Sinnwell JP, Dockter TJ, Suman VJ, Weinshilboum RM, Boughey JC, Goetz MP, Visscher DW, Wang L.
PMID: 31231469
Oncotarget. 2019 Jun 11;10(39):3924-3930. doi: 10.18632/oncotarget.27001. eCollection 2019 Jun 11.

Patient-derived xenografts (PDX) are generated in immune deficient mice and demonstrate histologic and molecular features similar to their corresponding human tumors. However, murine tumors (non-human) spontaneously occur in these models. 120 consecutive patients with high-risk primary breast cancer enrolled...

Cite
Moyer AM, Yu J, Sinnwell JP, et al. Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. Oncotarget. 2019;10(39):3924-3930doi: 10.18632/oncotarget.27001.
Moyer, A. M., Yu, J., Sinnwell, J. P., Dockter, T. J., Suman, V. J., Weinshilboum, R. M., Boughey, J. C., Goetz, M. P., Visscher, D. W., & Wang, L. (2019). Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. Oncotarget, 10(39), 3924-3930. https://doi.org/10.18632/oncotarget.27001
Moyer, Ann M, et al. "Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall." Oncotarget vol. 10,39 (2019): 3924-3930. doi: https://doi.org/10.18632/oncotarget.27001
Moyer AM, Yu J, Sinnwell JP, Dockter TJ, Suman VJ, Weinshilboum RM, Boughey JC, Goetz MP, Visscher DW, Wang L. Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. Oncotarget. 2019 Jun 11;10(39):3924-3930. doi: 10.18632/oncotarget.27001. eCollection 2019 Jun 11. PMID: 31231469; PMCID: PMC6570466.
Copy Download .nbib Format: NLM
Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma.

Translational oncology

Zakharia K, Miyabe K, Wang Y, Wu D, Moser CD, Borad MJ, Roberts LR.
PMID: 30316146
Transl Oncol. 2019 Jan;12(1):143-153. doi: 10.1016/j.tranon.2018.09.005. Epub 2018 Oct 11.

PURPOSE: We investigated the antitumor effect of the casein kinase II (CK2) inhibitor CX-4945 on cholangiocarcinoma (CCA).METHODS: We assessed the effect of CX-4945 alone and/or in combination with gemcitabine and cisplatin on cell viability, colony formation, and apoptosis of...

Cite
Zakharia K, Miyabe K, Wang Y, et al. Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. Transl Oncol. 2018;12(1):143-153doi: 10.1016/j.tranon.2018.09.005.
Zakharia, K., Miyabe, K., Wang, Y., Wu, D., Moser, C. D., Borad, M. J., & Roberts, L. R. (2019). Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. Translational oncology, 12(1), 143-153. https://doi.org/10.1016/j.tranon.2018.09.005
Zakharia, Kais, et al. "Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma." Translational oncology vol. 12,1 (2019): 143-153. doi: https://doi.org/10.1016/j.tranon.2018.09.005
Zakharia K, Miyabe K, Wang Y, Wu D, Moser CD, Borad MJ, Roberts LR. Preclinical In Vitro and In Vivo Evidence of an Antitumor Effect of CX-4945, a Casein Kinase II Inhibitor, in Cholangiocarcinoma. Transl Oncol. 2019 Jan;12(1):143-153. doi: 10.1016/j.tranon.2018.09.005. Epub 2018 Oct 11. PMID: 30316146; PMCID: PMC6187100.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 17 entries